Centers | ||
|
|
|
EU-OPENSCREEN | TEST | Edinburgh Drug Discovery |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
info here |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
Partnerships |
Events |
Jobs |
California Institute for Quantitative Biosciences (QB3) QB3 isa tri-campus organization at UC Berkeley, UC San Francisco, and UC Santa Cruz. QB3 is the University of California’s hub for innovation and entrepreneurship in the life sciences. The institute supports UC researchers and empowers... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all GSK and MD Anderson to co-develop new cancer therapeuticsGlaxoSmithkline and MD Anderson Cancer Center entered into a co-development and license agreement to develop antibody based therapeutics to treat cancer. Under this agreement MD Anderson grants exclusive rights to antibodies developed during the... View all |
No EVENTS for listing |
No Job Posts |
